A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer

A phase 1 clinical trial was conducted to assess the safety, tolerability, and preliminary efficacy of a heterologous prime-boost strategy involving plasmid DNA (pHM-GM-CSF, expressing truncated human epidermal growth factor receptor 2 (HER2) and granulocyte macrophage colony-stimulation factor (GM-...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sung-Bae, Ahn, Jin-Hee, Kim, Jeongeun, Jung, Kyung Hae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588449/
https://www.ncbi.nlm.nih.gov/pubmed/26445724
http://dx.doi.org/10.1038/mtm.2015.31

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588449/
https://www.ncbi.nlm.nih.gov/pubmed/26445724
http://dx.doi.org/10.1038/mtm.2015.31

Ejemplares similares